Huntsman and Clariant are in talks to merge in a transatlantic deal that would create a chemicals company valued at about $14 billion, according to a person familiar with the discussions.
The US and Swiss companies are discussing a deal in which Clariant would own about 52 percent of the new entity to be called Huntsman-Clariant, according to the person, who asked not to be identified discussing the talks. Huntsman Chief Executive Officer Peter Huntsman would hold that title for the combined company and the board would be evenly split, with Clariant CEO Hariolf Kottmann as chairman. An announcement may come as soon as Monday.
An agreement between Huntsman and Clariant would add to an already historic level of deals in the industry as CEOs seek to bolster tepid sales growth with acquisitions. Global chemical companies have more than $300 billion in M&A planned, according to a report by AT Kearney published in March. That level is more than twice the previous all-time high set at the end of 2015, according to the management consulting firm.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Doug Gurr Appointed Interim Chairman of UK’s Competition Authority
Jan 22, 2025 by
CPI
LinkedIn Faces Lawsuit Over Alleged Misuse of Customer Data for AI Training
Jan 22, 2025 by
Amanda Adams
Johns Hopkins and Caltech Settle for $35.3M in College Price-Fixing Lawsuit
Jan 22, 2025 by
CPI
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan